These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Evaluating Real-World Clinical Outcomes in Atrial Fibrillation Patients Receiving the WATCHMAN Left Atrial Appendage Closure Technology: Final 2-Year Outcome Data of the EWOLUTION Trial Focusing on History of Stroke and Hemorrhage. Boersma LV; Ince H; Kische S; Pokushalov E; Schmitz T; Schmidt B; Gori T; Meincke F; Protopopov AV; Betts T; Mazzone P; Foley D; Grygier M; Sievert H; De Potter T; Vireca E; Stein K; Bergmann MW; Circ Arrhythm Electrophysiol; 2019 Apr; 12(4):e006841. PubMed ID: 30939908 [TBL] [Abstract][Full Text] [Related]
9. Propensity-Matched Comparison of Oral Anticoagulation Versus Antiplatelet Therapy After Left Atrial Appendage Closure With WATCHMAN. Søndergaard L; Wong YH; Reddy VY; Boersma LVA; Bergmann MW; Doshi S; Kar S; Sievert H; Wehrenberg S; Stein K; Holmes DR JACC Cardiovasc Interv; 2019 Jun; 12(11):1055-1063. PubMed ID: 31171282 [TBL] [Abstract][Full Text] [Related]
10. Real-world experience with the new Watchman FLX device: Data from two high-volume Sicilian centers. The FLX-iEST registry. Vizzari G; Grasso C; Sardone A; Mazzone P; Laterra G; Frazzetto M; Sacchetta G; Micari A; Tamburino C; Contarini M Catheter Cardiovasc Interv; 2022 Jul; 100(1):154-160. PubMed ID: 35592941 [TBL] [Abstract][Full Text] [Related]
11. 5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials. Reddy VY; Doshi SK; Kar S; Gibson DN; Price MJ; Huber K; Horton RP; Buchbinder M; Neuzil P; Gordon NT; Holmes DR; J Am Coll Cardiol; 2017 Dec; 70(24):2964-2975. PubMed ID: 29103847 [TBL] [Abstract][Full Text] [Related]
12. Left atrial appendage closure device implantation in patients at very high risk for stroke. Hutt E; Wazni OM; Kaur S; Saliba WI; Tarakji KG; Kapadia S; Aguilera J; Barakat AF; Abdallah M; Jaber W; Rasmussen P; Hussain S; Uchino K; Wisco D; Lindsay BD; Kanj M; Hussein AA Heart Rhythm; 2020 Jan; 17(1):27-32. PubMed ID: 31302250 [TBL] [Abstract][Full Text] [Related]
13. Initial experience with the WATCHMAN™ left atrial appendage system for stroke prevention in atrial fibrillation: A single-centre registry. Bonnet G; Salaun E; Pankert M; Cuisset T; Bonnet JL Arch Cardiovasc Dis; 2016 Dec; 109(12):689-695. PubMed ID: 27594651 [TBL] [Abstract][Full Text] [Related]
14. Real-world safety and efficacy of WATCHMAN LAA closure at one year in patients on dual antiplatelet therapy: results of the DAPT subgroup from the EWOLUTION all-comers study. Bergmann MW; Ince H; Kische S; Schmitz T; Meincke F; Schmidt B; Foley D; Betts TR; Grygier M; Protopopov AV; Stein KM; Boersma LVA EuroIntervention; 2018 Apr; 13(17):2003-2011. PubMed ID: 29313819 [TBL] [Abstract][Full Text] [Related]
15. Feasibility of left atrial appendage device closure following chronically failed surgical ligation. Ellis CR; Metawee M; Piana RN; Bennett JM; Pretorius M; Deegan RJ Heart Rhythm; 2019 Jan; 16(1):12-17. PubMed ID: 30012348 [TBL] [Abstract][Full Text] [Related]
16. The clinical impact of incomplete left atrial appendage closure with the Watchman Device in patients with atrial fibrillation: a PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation) substudy. Viles-Gonzalez JF; Kar S; Douglas P; Dukkipati S; Feldman T; Horton R; Holmes D; Reddy VY J Am Coll Cardiol; 2012 Mar; 59(10):923-9. PubMed ID: 22381428 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-Year follow-up outcome data of the EWOLUTION trial. Boersma LV; Ince H; Kische S; Pokushalov E; Schmitz T; Schmidt B; Gori T; Meincke F; Protopopov AV; Betts T; Foley D; Sievert H; Mazzone P; De Potter T; Vireca E; Stein K; Bergmann MW; Heart Rhythm; 2017 Sep; 14(9):1302-1308. PubMed ID: 28577840 [TBL] [Abstract][Full Text] [Related]
18. Watchman FLX vs. Watchman 2.5 in a Dual-Center Left Atrial Appendage Closure Cohort: the WATCH-DUAL study. Galea R; Mahmoudi K; Gräni C; Elhadad S; Huber AT; Heg D; Siontis GCM; Brugger N; Sebag F; Windecker S; Valgimigli M; Landolff Q; Roten L; Amabile N; Räber L Europace; 2022 Oct; 24(9):1441-1450. PubMed ID: 35253840 [TBL] [Abstract][Full Text] [Related]
19. Computed tomography measurement of the left atrial appendage for optimal sizing of the Watchman device. Xu B; Betancor J; Sato K; Harb S; Abdur Rehman K; Patel K; Kumar A; Cremer PC; Jaber W; Rodriguez LL; Schoenhagen P; Wazni O J Cardiovasc Comput Tomogr; 2018; 12(1):50-55. PubMed ID: 29223726 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of percutaneous left atrial appendage closure to prevent thromboembolic events in atrial fibrillation patients with high stroke and bleeding risk. Seeger J; Bothner C; Dahme T; Gonska B; Scharnbeck D; Markovic S; Rottbauer W; Wöhrle J Clin Res Cardiol; 2016 Mar; 105(3):225-9. PubMed ID: 26318322 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]